March 4, 2024
(press release)
–
We are pleased to invite investors and analysts to participate in our virtual event on Monday, 11 March 2024, highlighting key data presented at 2024 Muscular Dystrophy Association (MDA) and Alzheimer's & Parkinson's Diseases (AD/PD) conferences.
15:00 – 16:30 CET / 14:00 – 15:30 GMT
10:00 – 11:30 AM EDT / 07:00 – 08:30 AM PDT
The webinar will start with presentations, followed by a Q&A session (live access to the speakers). The slides will be available for download at 14:00 CET on the day of the event. >click here
Agenda
Welcome
Bruno Eschli, Head of Investor Relations
Neurology franchise update
Paulo Fontoura, Senior Vice President and Global Head of Neuroscience, Immunology, Ophthalmology, Cardiometabolic, Infectious and Rare Diseases Clinical Development
Review of key EMBARK data presented at MDA
Alex Murphy, Senior Clinical Director
Review of key trotinemab and prasinezumab data presented at AD/PD
Azad Bonni, MD, PhD, Senior Vice President and Global Head of Neuroscience & Rare Diseases, Roche Pharma Research & Early Development
Q&A
Access to virtual event (pre-registration required)
Please pre-register for our webinar here.*
Should you be unable to register for the webinar due to your company IT policy, please send an email to investor.relations@roche.com.
A replay of the webinar will be available via > ir.roche.com
*privacy notice
Best regards,
Bruno Eschli
Head of Investor Relations
Loren Kalm
Head of Investor Relations, North America
Roche Investor Relations
Dr. Bruno Eschli
Phone: +41 61 68-75284
e-mail: bruno.eschli@roche.com
Dr. Sabine Borngräber
Phone: +41 61 68-88027
e-mail: sabine.borngraeber@roche.com
Dr. Birgit Masjost
Phone: +41 61 68-84814
e-mail: birgit.masjost@roche.com
Investor Relations North America
Loren Kalm
Phone: +1 650 225 3217
e-mail: kalm.loren@gene.com
* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.